Exosome Sciences’ research facility is being established within a Clinical Laboratory Improvement Amendments certified laboratory in Langhorne, Pennsylvania.
Aethlon Medical chairman and CEO Jim Joyce noted as a therapeutic organization, company’s primary focus is the clinical advancement and future commercialization of the Aethlon Hemopurifer in the US and abroad.
"With this mind, our objective with ESI is to transform a currently dormant and unvalued diagnostic asset into a stand-alone organization that contributes measurable asset value to Aethlon shareholders, yet does not dilute our team’s focus away from advancing first-in-class therapeutic devices.
"It also became clear that the launch of ESI might allow us to leverage recent valuations that have been awarded to molecular diagnostic organizations with novel technology strategies," Joyce added.
Aethlon Medical will contribute diagnostic related technology, including enzyme linked lectin specific assay (ELLSA), to Exosome Sciences.
ELLSA has been validated to identify the presence of exosomes underlying the human immunodeficiency virus, tuberculosis, and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
